Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2005-12-30
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT00271323
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2005-12-30
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 88
- Registration Number
- NCT00271284
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients
- Conditions
- First Posted Date
- 2005-12-30
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 40
- Registration Number
- NCT00271271
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma
- Conditions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2005-12-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 450
- Registration Number
- NCT00270348
FOCUS:Focus On Coronary Unstable Syndromes
- Conditions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00268619
IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)
- Conditions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00268632
Insulin Glargine in Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 534
- Registration Number
- NCT00268645
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
- Conditions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00268710
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)
- Conditions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT00268671
FOCUS Fatigue Outcome in Copaxone USers
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 111
- Registration Number
- NCT00267319
- Locations
- 🇨🇿
Sanofi-Aventis, Praha, Czech Republic